What are the drug contraindications for pomalidomide?

Pomalidomide is a targeted therapy drug mainly used for the treatment of bone tumor diseases such as multiple myeloma. It works by inhibiting tumor cell proliferation and inducing apoptosis, causing relatively little damage to normal tissue cells. However, there are some clear contraindications and precautions for the use of pomalidomide.

First, pomalidomide is strictly contraindicated during pregnancy. Because pomalidomide is potentially teratogenic, it may cause serious adverse effects on the fetus, including abnormalities in the nervous system, cardiovascular system, and limb development. Therefore, pomalidomide should be avoided if women are pregnant or planning to become pregnant. Women of childbearing potential need to take effective contraceptive measures before using pomalidomide, during treatment, and for at least four weeks after stopping the drug to avoid unwanted pregnancy.

Secondly, pomalidomide also has certain taboos for men of childbearing potential. Because pomalidomide may remain in the semen of male patients, male patients should use condoms and other contraceptive measures when having sex with women of childbearing age during the use of pomalidomide and within 28 days after stopping the drug. Additionally, male patients should not donate semen while taking pomalidomide.

In addition, the use of pomalidomide also needs to consider the patient's liver and kidney function. The use of pomalidomide may require special caution in patients with severe hepatic impairment and may require dose adjustment. At the same time, since pomalidomide may be secreted through breast milk, the drug should also be banned in breastfeeding women to avoid potential adverse effects on nursing infants.

In general, pomalidomide is an effective anti-tumor drug, but its use requires strict compliance with medical instructions and full consideration of the patient's specific situation and potential risks. For specific groups of people, such as pregnant women, lactating women, and men and women of childbearing potential, special attention needs to be paid to the contraindications and precautions for the use of the drug.

xa0

Reference materials:https://www.ema.europa.eu/en/documents/product-information/imnovid-epar-product-information_en.pdf